secwatch.observer — SEC 8-K summary
======================================

Issuer:     CITIUS ONCOLOGY, INC. (CTOR)
CIK:        0001851484
Form:       8-K
Filed at:   2024-08-16T23:59:59+00:00
Accession:  0001213900-24-070335
Event type: m_and_a
Sentiment:  positive
Materiality: 0.90
Item codes: 1.01, 2.01, 5.06, 9.01, 5.02, 3.02, 3.03, 4.01, 5.01, 5.03
LLM model:  deepseek-v4-flash:cloud@v2

Citius Oncology completes de-SPAC business combination; CTOR begins trading
---------------------------------------------------------------------------

- Citius Pharma received 65.6M shares (~92.6% ownership); 4.3M SPAC shares redeemed for ~$49.3M ($11.47 each).
- Company Common Stock began trading on Nasdaq Capital Market as 'CTOR' on August 13, 2024.
- Leonard Mazur appointed CEO & Chair; Jaime Bartushak CFO; Myron Holubiak Secretary/Treasurer; Myron Czuczman CMO.
- Citius Pharma contributed $10M capital; waivers include LYMPHIR trademark transfer within 60 days post-closing.
- 71.3M shares outstanding post-closing; board of 8 directors with staggered terms; controlled company under Nasdaq rules.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1851484/000121390024070335/0001213900-24-070335-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1851484/000121390024070335/ea0211423-8k_citius.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-070335

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer